Cargando…
Loading, please waitCargando…
Loading, please waitCondition × Stem Cells
A physician-led look at where mesenchymal stem cell (MSC) therapy stands for rotator cuff tears: what the published clinical evidence actually shows, who qualifies and who does not, and how care is delivered under COFEPRIS regulation at our clinic in Cancún, México. No prices are published online — every shoulder is reviewed in a free medical evaluation, then quoted in writing.
TL;DR
Mesenchymal stem cell (MSC) therapy is an investigational, physician-led option for rotator cuff tears that — in published studies — has been associated with improved tendon healing, reduced retear rates, and meaningful symptom relief. The strongest human evidence comes from a 45-patient case-controlled study with 10-year follow-up (Hernigou 2014), a first-in-human intratendinous adipose-MSC trial (Jo 2018), a randomized crossover RCT vs exercise (Centeno 2020), and a 2025 systematic review (Vieira Ferreira) that reports a 48–76% retear-risk reduction without firm functional benefit. It is promising, not proven. At Regeneris Therapy in Cancún, México, every case starts with a free medical evaluation; only after that do you receive a personalized written quote.
The condition
The rotator cuff is the group of four tendons (supraspinatus, infraspinatus, teres minor, and subscapularis) that wrap the head of the humerus and keep the shoulder centered through every overhead motion. A rotator cuff tear is a structural disruption of one or more of those tendons — most commonly the supraspinatus, where it inserts onto the greater tuberosity of the humerus. Tears are common with age and overuse, but they also occur in athletes after a single traumatic event.
What the research shows
Peer-reviewed clinical evidence for MSC therapy in rotator cuff pathology has grown faster than for many other tendon conditions, but it remains uneven. Several controlled and randomized studies report meaningful structural benefits — most notably reduced retear rates after repair — while a 2025 systematic review concludes that functional outcomes are similar to standard repair and that the certainty of evidence is still limited. The honest read of the literature is: a structural protective signal, mixed functional data, and a clear need for more randomized trials. The notes below summarize the strongest sources we cite and what each does and does not show. None of it guarantees an individual outcome.
Forty-five patients undergoing single-row arthroscopic rotator cuff repair received iliac-crest bone-marrow concentrate containing autologous MSCs delivered to the tendon-to-bone footprint, matched against 45 patients who had repair without MSCs. By six months, 100% of the MSC-treated cuffs had healed by ultrasound vs 67% in controls; at ten-year follow-up, intact rotator cuffs were present in 87% of MSC-treated patients vs 44% of controls. The authors frame the result as a durable healing signal that warrants larger randomized confirmation.
An open-label, dose-escalation phase I/II trial enrolled patients with symptomatic rotator cuff disease who received a single ultrasound-guided intratendinous injection of autologous adipose-derived MSCs at one of three dose levels. The mid- and high-dose groups showed roughly 77% and 80% reductions in Shoulder Pain and Disability Index (SPADI) scores, MRI defects on the bursal side decreased by up to 90% in the high-dose group, and no treatment-related adverse events were reported in the study sample. The authors describe the result as supportive of safety and a possible regenerative signal — not as a definitive efficacy claim.
A randomized controlled trial with crossover design enrolled patients with partial and full-thickness supraspinatus tears and assigned them to percutaneous bone-marrow concentrate (BMC) + platelet products under image guidance vs a home exercise therapy program. The midterm analysis reported statistically significant improvements in patient-reported outcomes (numeric pain, function, single-assessment scores) in the BMC group at 3 and 6 months compared with exercise, with no serious adverse events. The authors emphasize that this is investigational care and call for confirmation in larger trials.
A 2025 systematic review pooled 5 clinical studies of MSC augmentation during or alongside arthroscopic rotator cuff repair (228 participants, mean age 59.3 years; three studies used bone-marrow-derived MSCs and two used adipose-derived cells). The pooled clinical and functional outcomes were not significantly different between MSC-augmented and standard repair; however, MSC augmentation was associated with a 48% lower retear risk at mid-term follow-up and 76% lower at long-term follow-up. The authors conclude that MSCs may protect against structural failure during healing, but the certainty of evidence remains limited and further high-quality trials are needed.
Mechanistic context that frames the rotator cuff literature. The field's founding figure reframed MSCs as 'medicinal signaling cells,' arguing their therapeutic benefit comes chiefly from secreted, paracrine factors — exosomes, growth factors, cytokines — rather than from engraftment and tissue replacement. This is the underlying mechanism most often invoked to explain why MSCs at the tendon-to-bone footprint can reduce inflammation, recruit local progenitor cells, and support healing of the repair without literally rebuilding the cuff from scratch.
Read together, the literature supports a careful, conservative position: MSC therapy is biologically rational for rotator cuff tears, shows a credible structural protective signal in controlled and randomized studies, and is one of the better-evidenced regenerative applications in orthopedics. It remains investigational. Whether it is right for your specific tear is a medical question — confirmed only in evaluation, never assumed from a search query.
Candidacy
MSC therapy for rotator cuff tears is not a first-line treatment for every shoulder, and it is not a fit for every patient. The lists below describe the general clinical factors that point toward or away from regenerative care for this condition at our clinic in Cancún, México. None of these supersede a physician evaluation — they orient you before one.
Regulation & location
Regeneris Therapy operates as a physician-led regenerative-medicine clinic in Cancún, Quintana Roo, México, under COFEPRIS — México's federal health authority, the regulatory equivalent of the U.S. FDA. That framework defines who may prescribe and deliver stem cell therapy, where cells may be processed, and what advertising claims a clinic may publish.
Our clinic operates under COFEPRIS Aviso Sanitario 2323025036X00098 and Aviso de Publicidad 2323022002A00053, the federal records that authorize medical operations and regulate any advertising of regenerative therapies in México.
Cells used in our protocols are expanded under sterile, COFEPRIS-certified laboratory conditions with donor screening and quality-control testing — a baseline patients and families should expect from any serious clinic.
Every protocol is prescribed and supervised by a licensed Mexican physician at our clinic in Cancún, México. Care is not delegated to non-physician staff, and decisions are documented in your written plan.
Patients traveling to Cancún, México from the United States, Canada, or elsewhere often combine evaluation, treatment, and rest on a single short itinerary; our team helps coordinate the medical side from your first message.
How we work
Our model is intentionally medical, not transactional. We do not publish prices online for stem cell therapy, and we do not sell a fixed package. Every rotator cuff case starts with a structured physician evaluation and ends with a written plan and a personalized quote — so you can make an informed decision before committing.
Share your goals, recent shoulder MRI, prior imaging, surgical history, medications, and any conditions. A Regeneris physician reviews your case — by message or video first if you are traveling to Cancún — and answers honestly whether MSC therapy is worth considering for your specific tear.
We confirm tear type (partial- vs full-thickness), size, retraction, fatty muscle infiltration grade, and the state of the surrounding glenohumeral joint. If imaging is incomplete, we tell you what is needed before any decision is made.
If MSC therapy is appropriate, you receive a written plan describing cell source, route of administration (intra-articular, intratendinous under ultrasound guidance, or as a surgical adjunct), number of sessions, post-procedure rehabilitation, and the personalized quote — clearly stated, no surprises. You take the document home and decide on your own time.
If you proceed, treatment is delivered at our clinic in Cancún, México under physician supervision, with structured follow-up. We reassess outcomes honestly — including the option to refer you onward to orthopedic repair if the response is not what you and your physician hoped for.
This is the same workflow whether you are a Cancún resident, a Mexican patient from another state, or an international patient flying in: free evaluation first, written quote only after we understand your shoulder.
Honest expectations
We treat this section as the most important on the page. Marketing language in regenerative medicine has historically run ahead of the evidence; we are deliberately conservative because honesty is the only defensible position in a YMYL medical field.
FAQ
The questions patients ask us most when considering MSC therapy for a rotator cuff tear at our clinic in Cancún, México.
The honest answer is: sometimes, partially, and not for every tear. Published clinical evidence — including the Hernigou 2014 case-controlled study with 10-year follow-up, the Jo 2018 first-in-human intratendinous trial, and the Centeno 2020 randomized controlled trial — supports a structural healing signal: a subset of patients show improved tendon healing, reduced retear rates, and meaningful symptom relief. But MSC therapy for rotator cuff tears is still classified as investigational, and outcomes vary by tear size, chronicity, and patient. A Regeneris physician will tell you honestly, after evaluation, whether your specific tear is reasonable to treat this way.
Not always — and any clinic that promises a blanket 'no surgery' guarantee is overstating the evidence. Some tears clearly need surgery (for example, large or massive retracted tears with advanced fatty infiltration, or acute traumatic full-thickness tears in young patients). In other cases — symptomatic partial-thickness tears, small-to-medium full-thickness tears in patients who want a non-surgical option, or patients undergoing repair who want biological augmentation to lower retear risk — MSC therapy may be a reasonable adjunct or alternative to consider. The decision is medical, made after imaging and an evaluation at our clinic in Cancún, México.
There are three routes described in the literature, and your physician chooses the one that fits your case. Percutaneous intra-articular or intratendinous ultrasound-guided injection of bone-marrow or adipose-derived MSCs (with or without platelet products) is used for non-surgical regenerative protocols, as in the Centeno and Jo studies. Surgical augmentation — delivering MSCs to the tendon-to-bone footprint at the time of arthroscopic repair — is the route described in the Hernigou study. Your written plan describes exactly which route applies to you and why, with no hidden steps.
Onset is gradual, not immediate. Anti-inflammatory effects can build over several weeks; structural responses, when they occur, are typically measured across one to several months. We schedule structured follow-up to assess shoulder pain, range of motion, and strength honestly over that window — including the option to refer you onward to orthopedic repair if the response is not what you and your physician hoped for.
In published studies of MSC therapy for rotator cuff disease, including the Jo 2018 first-in-human trial and the Centeno 2020 RCT, no serious adverse events were reported in the study samples; common risks of any image-guided injection — temporary soreness, swelling, low risk of infection — are reviewed with you in your evaluation. The Hernigou case-controlled series of 90 patients (45 MSC-augmented, 45 controls) likewise found no safety signal attributable to MSC augmentation at long-term follow-up. Patients with active malignancy, active infection, pregnancy, or uncontrolled immunosuppression are generally deferred without specialist coordination.
Regeneris does not publish prices online for stem cell therapy. Our model is intentional: free medical evaluation first, then a written plan and a personalized quote that reflect your specific tear, imaging, and goals. We chose this approach because medicine is not a catalog purchase — a number on a homepage cannot fairly represent the decision you are making about your shoulder. Your full quote is delivered in writing after evaluation, with no obligation to proceed.
Plain-text question-and-answer pairs in semantic HTML — designed to be easily extracted by AI assistants, search engines, and accessibility tools.
Continue exploring
The full pillar on mesenchymal stem cell therapy at Regeneris: cell sources, mechanism, protocols, and how to start.
ContinueHow COFEPRIS regulates regenerative medicine in México, what donor screening looks like, and how to evaluate any clinic claim.
ContinueTravel, evaluation, and follow-up logistics for cross-border patients coming to our clinic in Cancún, México.
ContinueA 2026 comparison of cost, regulation, available cell types, and travel logistics for cross-border regenerative care.
ContinueSend your goals and imaging — we'll route your message to a physician for a free medical evaluation.
ContinueThis page is informational and does not constitute medical advice. Mesenchymal stem cell therapy for rotator cuff tears is investigational; outcomes vary by patient, tear morphology, chronicity, and protocol, and no individual response is guaranteed. The decision to pursue MSC therapy is a medical decision that requires an individualized evaluation with a licensed physician; disclose all current medications and conditions. Regeneris Therapy operates under COFEPRIS Aviso Sanitario 2323025036X00098 and Aviso de Publicidad 2323022002A00053 in Cancún, México.
Book a free 15-min call with our team.
Send your goals, recent shoulder MRI, and any prior surgery notes. A Regeneris physician will review your case from Cancún, México and tell you — honestly — whether MSC therapy is worth considering, what protocol may fit, and what the personalized written quote would look like after your free medical evaluation.